Wolverine Trading, LLC Exelixis, Inc. Call Options Transaction History

Wolverine Trading, LLC

$93.9 Billion
Q3 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $57,096 - $71,760	-2,600 Reduced 5.05%	48,900 $1.27 Million
Q2 2024 Aug 14, 2024	SELL	$20.34 - $23.73 $441,378 - $514,941	-21,700 Reduced 29.64%	51,500 $1.16 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $167,411 - $198,619	8,300 Added 12.79%	73,200 $1.74 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $1.25 Million - $1.57 Million	64,900 New	64,900 $1.56 Million
Q2 2023 Aug 23, 2023	BUY	$18.17 - $20.48 $141,726 - $159,744	7,800 Added 41.71%	26,500 $506,000
Q1 2023 May 15, 2023	SELL	$16.3 - $19.41 $337,410 - $401,787	-20,700 Reduced 52.54%	18,700 $352,000
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $5,984 - $6,956	400 Added 1.03%	39,400 $632,000
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $164,640 - $233,835	10,500 Added 36.84%	39,000 $618,000
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $81,968 - $108,852	4,700 Added 19.75%	28,500 $593,000
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $189,033 - $251,637	11,100 Added 87.4%	23,800 $534,000
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $259,776 - $358,832	-16,400 Reduced 56.36%	12,700 $237,000
Q3 2021 Nov 12, 2021	BUY	$16.3 - $21.14 $44,010 - $57,078	2,700 Added 10.23%	29,100 $600,000
Q2 2021 Aug 06, 2021	BUY	$17.95 - $25.56 $125,650 - $178,920	7,000 Added 36.08%	26,400 $474,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $164,240 - $201,760	-8,000 Reduced 29.2%	19,400 $426,000
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $121,374 - $163,680	-6,600 Reduced 19.41%	27,400 $554,000
Q3 2020 Nov 13, 2020	SELL	$20.67 - $26.94 $624,234 - $813,588	-30,200 Reduced 47.04%	34,000 $833,000
Q2 2020 Aug 13, 2020	SELL	$16.46 - $27.42 $67,486 - $112,422	-4,100 Reduced 6.0%	64,200 $1.46 Million
Q1 2020 May 11, 2020	BUY	$14.46 - $21.8 $221,238 - $333,540	15,300 Added 28.87%	68,300 $1.21 Million
Q4 2019 Feb 12, 2020	SELL	$15.15 - $18.89 $536,310 - $668,706	-35,400 Reduced 40.05%	53,000 $939,000
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $312,936 - $400,905	17,700 Added 25.04%	88,400 $1.59 Million
Q2 2019 Aug 20, 2019	BUY	$18.93 - $24.75 $825,348 - $1.08 Million	43,600 Added 160.89%	70,700 $1.51 Million
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $98,000 - $123,800	-5,000 Reduced 15.58%	27,100 $645,000
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $182,910 - $292,120	-13,400 Reduced 29.45%	32,100 $624,000
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $350,727 - $495,039	-22,100 Reduced 32.69%	45,500 $806,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $934,729 - $1.35 Million	-42,200 Reduced 38.43%	67,600 $1.5 Million
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $787,475 - $1.01 Million	32,500 Added 42.04%	109,800 $3.34 Million
Q3 2017 Nov 15, 2017	BUY	$23.35 - $29.24 $1.8 Million - $2.26 Million	77,300	77,300 $1.87 Million

Others Institutions Holding EXEL

# of Institutions

502

Shares Held

243M

Call Options Held

2.54M

Put Options Held

2.29M

Black Rock Inc. New York, NY

33.5M
Shares

$1.12 Billion
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

29.3M
Shares

$976 Million
0.01% of portfolio
Farallon Capital Management LLC San Francisco, CA

25.4M
Shares

$846 Million
3.31% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

15.4M
Shares

$511 Million
0.63% of portfolio
State Street Corp Boston, MA

11.4M
Shares

$381 Million
0.01% of portfolio

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.7B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.

Account